PTJ
DNA icon

Paul Tudor Jones’s Ginkgo Bioworks DNA Stock Holding History

Paul Tudor Jones’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-273
Closed -$25K – 2389
2022
Q2 		$25K Buy
+273
New +$33.3K ﹤0.01% 2004

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Paul Tudor Jones's DNA Position: Q2 2026 in Review

Paul Tudor Jones reduced its Ginkgo Bioworks (DNA) stake by 28% in Q2 2026, selling an estimated $1.08M and leaving 335,710 shares worth $3.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1574.

Paul Tudor Jones first reported a position in DNA in Q1 2022 and has held it in 7 quarters since. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Paul Tudor Jones held 335,710 shares of Ginkgo Bioworks worth $3.33M as of Q2 2026.
  • Paul Tudor Jones sold 128,953 Ginkgo Bioworks shares in Q2 2026, an estimated $1.08M.
  • Ginkgo Bioworks made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1574 holding.
  • Paul Tudor Jones first reported a position in Ginkgo Bioworks in Q1 2022 and has held it in 7 quarters since.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.